Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Non-Current Liabilities (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $3.0 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities rose 111.14% year-over-year to $3.0 million; the TTM value through Mar 2026 reached $3.0 million, up 111.14%, while the annual FY2025 figure was $1.5 million, 44.3% down from the prior year.
  • Other Non-Current Liabilities hit $3.0 million in Q1 2026 for Barinthus Biotherapeutics, up from $1.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.0 million in Q1 2026 and bottomed at $711000.0 in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $1.6 million, with a median of $1.5 million recorded in 2025.
  • Year-over-year, Other Non-Current Liabilities crashed 59.3% in 2022 and then skyrocketed 152.74% in 2023.
  • Barinthus Biotherapeutics' Other Non-Current Liabilities stood at $965000.0 in 2022, then skyrocketed by 37.31% to $1.3 million in 2023, then skyrocketed by 100.0% to $2.6 million in 2024, then plummeted by 44.3% to $1.5 million in 2025, then surged by 100.27% to $3.0 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $3.0 million, $1.5 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.